W
WAVEMAN · COMPANY
NWBO · Northwest Biotherapeutics Inc
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

NWBO

NORTHWEST BIOTHERAPEUTICS INC
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001072379
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
3
13F, latest reported quarter
REVENUE GROWTH
-0.3%
XBRL, annual
NET MARGIN
-4365.9%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
3 funds added or opened last quarter
below 98% of Pharma & Biotech
REVENUE
-0.3% year over year
below 57% of Pharma & Biotech
MARGIN
-4365.9% net margin
below 97% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
4.1% of shares outstanding short · 10.8 days to cover · settled 2026-07-31
below 51% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -37.3%
-37.3%12M
-44%-23%-2%+19%2025-092025-102025-122026-032026-052026-072026-09
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows 3 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for NORTHWEST BIOTHERAPEUTICS INC in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
MALIK NAVID
Director
SELL
2023-11-17
295,000.0
$241.9K
MALIK NAVID
Director
SELL
2023-11-17
150,000.0
$123.0K
MALIK NAVID
Director
SELL
2023-11-16
125,000.0
$105.0K
3 TRANSACTIONS ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
COMPASS FINANCIAL MANAGEMENT LLC
1,215,500.0 sh
$227.1K
KELLEHER FINANCIAL ADVISORS
800,000.0 sh
$149.4K
VSM Wealth Advisory, LLC
80,574.0 sh
$15.1K
Ethos Financial Group, LLC
39,070.0 sh
$6.3K
Williams Jones Wealth Management, LLC.
25,000.0 sh
$4.7K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$1.4M$1.4M$1.9M$1.7M
OPERATING INCOME$-59.9M$-66.5M$-55.5M$-67.2M
NET INCOME$-60.2M$-83.8M$-62.6M$-105.0M
EPS (DILUTED)-0.04-0.07-0.06-0.10
OPERATING CASH FLOW$-44.8M$-57.0M$-53.6M$-52.8M
CASH$3.0M$2.2M$2.1M$7.0M
LONG-TERM DEBT$60.0M$62.7M$40.8M$21.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →